This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Alberta directory, so their courses and email address may be missing. Find their university profile.
Latest papers
Single-cell genomic analysis of cancer cells from one treatment-naïve patient with metastatic prostate cancer.
BMC genomic data · 2026
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
American journal of hematology · 2022
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
American journal of hematology · 2021
Latest funding
- $3,056,172
A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma
CIHR · 2023 · Co-investigator
- $147,354
A randomized phase II trial of bortezomib-based therapy plus doxycycline vs. bortezomib-based chemotherapy plus standard supportive therapy in cardiac AL amyloidosis
CIHR · 2016 · Nominated PI
6 publications.
Single-cell genomic analysis of cancer cells from one treatment-naïve patient with metastatic prostate cancer.
Jovel J, Polzer B, Patterson J, Yong H, Vasquez C, O'keefe S, Pink D, Li G, Fairey A, Adam B, Teitelbaum J, Salimi A, Kirsh S, Alberter B, Lowes L, Carpenter E, Kolinsky M, Zhu Z, Zhou Q, Venner P, Venner C, Williams D, Allan A, Boutros PC, Klein CA, Wong G, Lewis JD
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Sanchorawala V, Palladini G, Minnema MC, Jaccard A, Lee HC, Gibbs S, Mollee P, Venner C, Lu J, Schönland S, Gatt M, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Chauveau D, Gries KS, Fastenau J, Tran NP, Qin X, Vasey SY, Weiss BM, Vermeulen J, Ho KF, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Sanchez L, Leleu X, Beaumont JL, Yu H, Hudgens S, Simonova M, Auner HW, Quach H, Delimpasi S, Špička I, Pour L, Kriachok I, Dimopoulos MA, Usenko G, Hájek R, Benjamin R, Sinha DK, Venner C, Illmer T, Garg MK, Stevens DA, Jagannath S, Levy M, Anderson LD, Bahlis NJ, Facon T, Cavo M, Chai Y, Ma X, Tang S, Leong H, Shah J, Shacham S, Kauffman M, Richardson P, Grosicki S
Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism.
Huang YH, Almowaled M, Li J, Venner C, Sandhu I, Peters A, Lavasanifar A, Lai R
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
Jimenez-Zepeda VH, Venner C, McCurdy A, Masih-Khan E, Atenafu EG, Sebag M, Stakiw J, Song K, LeBlanc R, Reiman T, Louzada M, Kotb R, Gul E, Reece D
Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.
Sachchithanantham S, Offer M, Venner C, Mahmood SA, Foard D, Rannigan L, Lane T, Gillmore JD, Lachmann HJ, Hawkins PN, Wechalekar AD
A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma
Principal investigators: Hay, Annette; Mian, Hira
Keywords: De-Escalation; Economic Analysis; Multiple Myeloma; Quality Of Life; Randomized Phase Iii Trial
A randomized phase II trial of bortezomib-based therapy plus doxycycline vs. bortezomib-based chemotherapy plus standard supportive therapy in cardiac AL amyloidosis
Principal investigators: Venner, Christopher P
Keywords: Amyloidosis; Cardiac Failure; Light Chain; Plasma Cell Dyscrasia
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Department of Anatomy & Cell Biology
- Department of Medicine
- Department of Epidemiology and Biostatistics
- Oncology
- Medicine
- Other
Co-authors at University of Alberta, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Alison Allan
Department of Anatomy & Cell Biology
1 shared papers, latest 2026
Michael Kolinsky
Oncology
1 shared papers, latest 2026
Arleigh McCurdy
Department of Medicine
1 shared papers, latest 2021
Martha Louzada
Department of Epidemiology and Biostatistics
1 shared papers, latest 2021
Michael Sebag
Medicine
1 shared papers, latest 2021
Afsaneh Lavasanifar
Faculty
1 shared papers, latest 2021
Donna Reece
Faculty
1 shared papers, latest 2021
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.